{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:15:53Z","timestamp":1787904953249,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jcf.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:45:43Z","timestamp":1748868343000},"page":"710-715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term outcomes in people with CF lacking FEV1 response to elexacaftor\/tezacaftor\/ivacaftor therapy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-379X","authenticated-orcid":false,"given":"Mohamad","family":"Hadhud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Halevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2565-4185","authenticated-orcid":false,"given":"Joel","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4032-1039","authenticated-orcid":false,"given":"Elad Ben","family":"Meir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Gileles-Hillel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-0212","authenticated-orcid":false,"given":"Ido","family":"Sadras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4635-386X","authenticated-orcid":false,"given":"Eitan","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Cohen-Cymberknoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9095","authenticated-orcid":false,"given":"Oded","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.05.005_bib0001","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0002","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.05.005_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0004","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0005","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0006","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0007","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1164\/rccm.202309-1646ED","article-title":"Sustained improvement of cystic fibrosis lung disease following initiation of elexacaftor\/tezacaftor\/ivacaftor therapy: lessons from real-world studies","volume":"208","author":"Steinke","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0008","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jcf.2022.03.011","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"21","author":"Wucherpfennig","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.05.005_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.05.005_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with Elexacaftor\/Tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older - the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2024.03.033","article-title":"Relationship between lung volumes and heterogeneity in the response to elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced Lung disease","author":"Gramegna","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2025.05.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.001","article-title":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","author":"Zemanick","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.05.005_bib0013","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.05.005_bib0014","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-023-02451-0","article-title":"Heterogeneity of weight gain after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis","volume":"24","author":"Gramegna","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.jcf.2025.05.005_bib0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcf.2018.03.013","article-title":"The CF Canada-sick kids program in individual CF therapy: a resource for the advancement of personalized medicine in CF","volume":"18","author":"Eckford","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.05.005_bib0016","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jcf.2023.04.013","article-title":"Cost-effectiveness analysis of genetic tools to predict treatment response in patients with cystic fibrosis","volume":"22","author":"Sahakyan","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.05.005_bib0017","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.05.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0019","unstructured":"Food and Drug Administration. Trikafta. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf (accessed Nov 13, 2022) n.d."},{"key":"10.1016\/j.jcf.2025.05.005_bib0020","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1183\/20734735.012717","article-title":"The Global Lung Function Initiative (GLI) network: bringing the world\u2019s respiratory reference values together","volume":"13","author":"Cooper","year":"2017","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.jcf.2025.05.005_bib0021","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1164\/rccm.200503-401PP","article-title":"Computed tomography in the evaluation of cystic fibrosis lung disease","volume":"172","author":"Brody","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.rti.0000203937.82276.ce","article-title":"Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis","volume":"21","author":"Brody","year":"2006","journal-title":"J Thorac Imaging"},{"key":"10.1016\/j.jcf.2025.05.005_bib0023","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1378\/chest.12-1226","article-title":"Differences in the pattern of structural abnormalities on CT scan in patients with cystic fibrosis and pancreatic sufficiency or insufficiency","volume":"144","author":"Simanovsky","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2025.05.005_bib0024","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.200603-343OC","article-title":"Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis","volume":"175","author":"Davis","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.04.013","article-title":"Heterogeneity in response to Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis","author":"Alicandro","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.05.005_bib0026","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S2213-2600(24)00205-4","article-title":"Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial","volume":"12","author":"Solomon","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.05.005_bib0027","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jcf.2016.05.014","article-title":"Physiologic endpoints for clinical studies for cystic fibrosis","volume":"15","author":"Stanojevic","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.05.005_bib0028","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2025.05.005_bib0029","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcf.2023.10.010","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis","volume":"23","author":"Donaldson","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.05.005_bib0030","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1164\/rccm.202310-1836OC","article-title":"Pharmacological improvement of Cystic fibrosis transmembrane conductance regulator function rescues airway epithelial homeostasis and host defense in children with Cystic Fibrosis","volume":"209","author":"Loske","year":"2024","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:16:05Z","timestamp":1778822165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325014869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1569199325014869"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.05.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes in people with CF lacking FEV1 response to elexacaftor\/tezacaftor\/ivacaftor therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}